Boston Scientific Corporation (BSX) has seen numerous developments, influencing its market performance. On one end, the company's quarterly earnings previews show potential for growth, while an analyst at Needham has downgraded the BSX stock from Buy to Hold. Despite a brief dip in performance, BSX has consistently hit new 52-week highs, indicating an upward trend. Boston Scientific recently completed the acquisition of
Silk Road Medical, Inc, a strategic move likely impacting its stock value. The company's shares, however, have been sold by Bleakley Financial Group and Exchange Traded Concepts. Despite such sales,
CHB Investment Group and
Watkins Advises have made fresh purchases of BSX shares. Giving investors optimism, it has been working on its
Farapulse Line which could positively influence Q3 Earnings. Furthermore, a positive outlook on Boston Scientific remains dominant among Wall Street Analysts, who feel their investments in BSX are worth the risk.
Boston Scientific Corp BSX News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sat, 19 Oct 2024 08:37:08 GMT -
Rating 6
- Innovation 6
- Information 8
- Rumor -2
